China Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays [Protein, DNA, RNA, Tissue], Software), Application (Research, Clinical), End User - Forecast to 2031
China Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays {Protein, DNA, RNA, Tissue}, Software) Application (Research, Clinical), End User—Forecast to 2031
The China neurogenomics market is projected to reach $ 562.1 million by 2031 at a CAGR of 19.4% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.
The growth of the China neurogenomics market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the rising utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for early detection & prevention of neurological diseases, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high prices of neurogenomics products, the low chances of identifying positive, actionable mutations for precision medicine, and ethical & legal issues related to sequencing-based diagnosis are factors restraining the growth of this market.
Furthermore, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to generate growth opportunities for market stakeholders. However, the dynamic regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the shortage of sequencing professionals in the country, and the high capital investments required for sequencing setups are major challenges impacting the growth of the China neurogenomics market.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years (2021–2024). The key players operating in the China neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).
Among all offerings studied in this report, in 2024, the next-generation sequencing (NGS) segment is expected to hold a significant share of 64.1% of the China neurogenomics market. This segment's large share is attributed to the rising demand for next-generation sequencing solutions from end users, the recurring use of sample preparation consumables in neurological research, increasing affordability, and the rise in genomic studies in the country.
Among all the applications studied in this report, in 2024, the research applications segment is expected to dominate the China neurogenomics market with a 61.4% share. This large market share is attributed to the decreasing cost of advanced solutions used in neurogenomics, increasing R&D by pharmaceutical and biotechnology companies for precision medicine and drug discovery, and the use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.
Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is anticipated to hold a dominant share of 44.5% of the China neurogenomics market. The large market share of this segment is attributed to the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of neurological diseases, which drive the adoption of advanced products among pharmaceutical & biotechnology companies.
Scope of the Report:
China Neurogenomics Market Assessment—by Offering
The China neurogenomics market is projected to reach $ 562.1 million by 2031 at a CAGR of 19.4% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.
The growth of the China neurogenomics market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the rising utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for early detection & prevention of neurological diseases, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high prices of neurogenomics products, the low chances of identifying positive, actionable mutations for precision medicine, and ethical & legal issues related to sequencing-based diagnosis are factors restraining the growth of this market.
Furthermore, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to generate growth opportunities for market stakeholders. However, the dynamic regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the shortage of sequencing professionals in the country, and the high capital investments required for sequencing setups are major challenges impacting the growth of the China neurogenomics market.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years (2021–2024). The key players operating in the China neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).
Among all offerings studied in this report, in 2024, the next-generation sequencing (NGS) segment is expected to hold a significant share of 64.1% of the China neurogenomics market. This segment's large share is attributed to the rising demand for next-generation sequencing solutions from end users, the recurring use of sample preparation consumables in neurological research, increasing affordability, and the rise in genomic studies in the country.
Among all the applications studied in this report, in 2024, the research applications segment is expected to dominate the China neurogenomics market with a 61.4% share. This large market share is attributed to the decreasing cost of advanced solutions used in neurogenomics, increasing R&D by pharmaceutical and biotechnology companies for precision medicine and drug discovery, and the use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.
Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is anticipated to hold a dominant share of 44.5% of the China neurogenomics market. The large market share of this segment is attributed to the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of neurological diseases, which drive the adoption of advanced products among pharmaceutical & biotechnology companies.
Scope of the Report:
China Neurogenomics Market Assessment—by Offering
- Next-generation Sequencing
- Systems
- Kits & Reagents
- DNA Extraction and Amplification Kits & Reagents
- Library Preparation & Target Enrichment Kits & Reagents
- Quality Control Kits & Reagents
- Other Kits & Reagents
- Polymerase Chain Reaction (PCR)
- Systems
- Kits & Reagents
- Microarray
- Readers & Scanners
- Kits & Reagents
- DNA & RNA Microarray Kits & Reagents
- Protein Microarray Kits & Reagents
- Tissue Microarray Kits & Reagents
- Software & Services
- Research Applications
- Target identification
- Functional Studies
- Variant Discovery
- Transcription Factor Binding Analysis
- Clinical Applications
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Hospitals & Diagnostic Laboratories
1. INTRODUCTION
1.1 Market Definition
1.2 Market Ecosystem
1.3 Currency & Limitations
1.4 Key Stakeholders
2. RESEARCH METHODOLOGY
2.1 Research Approach
2.2 Data Collection & Validation Process
2.2.1 Secondary Research
2.2.2 Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3 Market Sizing & Forecasting
2.3.1 Market Size Estimation Approach
2.3.2 Market Share Analysis of Key Players
2.3.3 Growth Forecast Approach
2.4 Assumptions for the Study
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1 Overview
4.2 Factors Affecting Market Growth
4.2.1 Impact Analysis of Market Dynamics
4.2.2 Factor Analysis
4.3 Pricing Analysis
4.4 Regulatory Analysis
4.5 Porter’s Five Forces Analysis
5. CHINA NEUROGENOMICS MARKET ASSESSMENT—BY OFFERING
5.1 Overview
5.2 Next-generation Sequencing (NGS)
5.2.1 Systems
5.2.2 Kits & Reagents
5.2.2.1 DNA Extraction & Amplification Kits & Reagents
5.2.2.2 Library Preparation & Target Enrichment Kits & Reagents
5.2.2.3 Quality Control Kits & Reagents
5.2.2.4 Other NGS Kits & Reagents
5.3 Polymerase Chain Reaction (PCR)
5.3.1 Systems
5.3.2 Kits & Reagents
5.4 Microarray
5.4.1 Readers & Scanners
5.4.2 Kits & Reagents
5.4.2.1 DNA & RNA Microarray Kits & Reagents
5.4.2.2 Protein Microarray Kits & Reagents
5.4.2.3 Tissue Microarray Kits & Reagents
5.5 Software & Services
6. CHINA NEUROGENOMICS MARKET ASSESSMENT—BY APPLICATION
6.1 Overview
6.2 Research Applications
6.2.1 Target Identification
6.2.2 Transcription Factor Binding Analysis
6.2.3 Functional Studies
6.2.4 Variant Discovery
6.3 Clinical Applications
7. CHINA NEUROGENOMICS MARKET ASSESSMENT—BY END USER
7.1 Overview
7.2 Pharmaceutical & Biotechnology Companies
7.3 Hospitals & Diagnostic Laboratories
7.4 Academic & Research Institutes
8. COMPETITION ANALYSIS
8.1 Overview
8.2 Key Growth Strategies
8.3 Competitive Benchmarking
8.4 Competitive Dashboard
8.4.1 Industry Leaders
8.4.2 Market Differentiators
8.4.3 Vanguards
8.4.4 Emerging Companies
8.5 Market Share Analysis (2023)
8.5.1 Illumina, Inc. (U.S.)
8.5.2 MGI Tech Co., Ltd. (China)
8.5.3 Thermo Fisher Scientific Inc. (U.S.)
8.5.4 F. Hoffmann-La Roche Ltd. (Switzerland)
8.5.5 Revvity, Inc. (U.S.)
9 . COMPANY PROFILES (COMPANY OVERVIEW, FINANCIAL OVERVIEW, PRODUCT PORTFOLIOS, STRATEGIC DEVELOPMENTS, AND SWOT ANALYSIS)
9.1 Illumina, Inc. (U.S.)
9.2 Thermo Fisher Scientific Inc.
9.3 F. Hoffmann-La Roche Ltd
9.4 MGI Tech Co., Ltd.
9.5 Agilent Technologies, Inc.
9.6 Revvity, Inc.
9.7 Qiagen N.V.
9.8 Pacific Biosciences of California Inc.
9.9 Danaher Corporation
9.10 Oxford Nanopore Technologies Plc.
(Note: SWOT Analysis will be provided for the top 5 market players.)
10. RELATED REPORTS
Table 1 China: List of Personalized Medicine (PM)-related Policy Measures
Table 2 China: Proportion of Brain Tumor Histology and Malignancy Status, by Age Subgroup, 2019-2020
Table 3 China: Data on the Disease Burden of AD and Other Dementias in Each Province, Autonomous Region, and Municipality Directly Under the Central Government, 2021 (Per 100,000 Population)
Table 4 China: Major Genome Sequencing Projects
Table 5 China: Brain Tumor Centers
Table 6 Sequencing Kits & Reagents/Consumables: Pricing
Table 7 Sequencing Instruments: Product Description & Pricing
Table 8 PCR Consumables & Instruments: Pricing
Table 9 Regulatory Authorities Governing In Vitro Diagnostics, by Country/Region
Table 10 China Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 11 China Neurogenomics Market for Next-generation Sequencing (NGS), by Product, 2022–2031 (USD Million)
Table 12 China Next-generation Sequencing (NGS) Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 13 China Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 14 China Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 15 China Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 16 China Neurogenomics Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 17 China Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 18 Recent Developments, by Company, 2021-2024
1.1 Market Definition
1.2 Market Ecosystem
1.3 Currency & Limitations
1.4 Key Stakeholders
2. RESEARCH METHODOLOGY
2.1 Research Approach
2.2 Data Collection & Validation Process
2.2.1 Secondary Research
2.2.2 Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3 Market Sizing & Forecasting
2.3.1 Market Size Estimation Approach
2.3.2 Market Share Analysis of Key Players
2.3.3 Growth Forecast Approach
2.4 Assumptions for the Study
3. EXECUTIVE SUMMARY
4. MARKET INSIGHTS
4.1 Overview
4.2 Factors Affecting Market Growth
4.2.1 Impact Analysis of Market Dynamics
4.2.2 Factor Analysis
4.3 Pricing Analysis
4.4 Regulatory Analysis
4.5 Porter’s Five Forces Analysis
5. CHINA NEUROGENOMICS MARKET ASSESSMENT—BY OFFERING
5.1 Overview
5.2 Next-generation Sequencing (NGS)
5.2.1 Systems
5.2.2 Kits & Reagents
5.2.2.1 DNA Extraction & Amplification Kits & Reagents
5.2.2.2 Library Preparation & Target Enrichment Kits & Reagents
5.2.2.3 Quality Control Kits & Reagents
5.2.2.4 Other NGS Kits & Reagents
5.3 Polymerase Chain Reaction (PCR)
5.3.1 Systems
5.3.2 Kits & Reagents
5.4 Microarray
5.4.1 Readers & Scanners
5.4.2 Kits & Reagents
5.4.2.1 DNA & RNA Microarray Kits & Reagents
5.4.2.2 Protein Microarray Kits & Reagents
5.4.2.3 Tissue Microarray Kits & Reagents
5.5 Software & Services
6. CHINA NEUROGENOMICS MARKET ASSESSMENT—BY APPLICATION
6.1 Overview
6.2 Research Applications
6.2.1 Target Identification
6.2.2 Transcription Factor Binding Analysis
6.2.3 Functional Studies
6.2.4 Variant Discovery
6.3 Clinical Applications
7. CHINA NEUROGENOMICS MARKET ASSESSMENT—BY END USER
7.1 Overview
7.2 Pharmaceutical & Biotechnology Companies
7.3 Hospitals & Diagnostic Laboratories
7.4 Academic & Research Institutes
8. COMPETITION ANALYSIS
8.1 Overview
8.2 Key Growth Strategies
8.3 Competitive Benchmarking
8.4 Competitive Dashboard
8.4.1 Industry Leaders
8.4.2 Market Differentiators
8.4.3 Vanguards
8.4.4 Emerging Companies
8.5 Market Share Analysis (2023)
8.5.1 Illumina, Inc. (U.S.)
8.5.2 MGI Tech Co., Ltd. (China)
8.5.3 Thermo Fisher Scientific Inc. (U.S.)
8.5.4 F. Hoffmann-La Roche Ltd. (Switzerland)
8.5.5 Revvity, Inc. (U.S.)
9 . COMPANY PROFILES (COMPANY OVERVIEW, FINANCIAL OVERVIEW, PRODUCT PORTFOLIOS, STRATEGIC DEVELOPMENTS, AND SWOT ANALYSIS)
9.1 Illumina, Inc. (U.S.)
9.2 Thermo Fisher Scientific Inc.
9.3 F. Hoffmann-La Roche Ltd
9.4 MGI Tech Co., Ltd.
9.5 Agilent Technologies, Inc.
9.6 Revvity, Inc.
9.7 Qiagen N.V.
9.8 Pacific Biosciences of California Inc.
9.9 Danaher Corporation
9.10 Oxford Nanopore Technologies Plc.
(Note: SWOT Analysis will be provided for the top 5 market players.)
10. RELATED REPORTS
Table 1 China: List of Personalized Medicine (PM)-related Policy Measures
Table 2 China: Proportion of Brain Tumor Histology and Malignancy Status, by Age Subgroup, 2019-2020
Table 3 China: Data on the Disease Burden of AD and Other Dementias in Each Province, Autonomous Region, and Municipality Directly Under the Central Government, 2021 (Per 100,000 Population)
Table 4 China: Major Genome Sequencing Projects
Table 5 China: Brain Tumor Centers
Table 6 Sequencing Kits & Reagents/Consumables: Pricing
Table 7 Sequencing Instruments: Product Description & Pricing
Table 8 PCR Consumables & Instruments: Pricing
Table 9 Regulatory Authorities Governing In Vitro Diagnostics, by Country/Region
Table 10 China Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 11 China Neurogenomics Market for Next-generation Sequencing (NGS), by Product, 2022–2031 (USD Million)
Table 12 China Next-generation Sequencing (NGS) Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 13 China Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 14 China Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 15 China Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 16 China Neurogenomics Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 17 China Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 18 Recent Developments, by Company, 2021-2024
